Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.

https://mma.prnewswire.com/media/1390052/nektar_logo.jpg

The presentation and Q&A session will be accessible via a webcast through a link posted on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. This webcast will be available for replay until April 28, 2024.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Other pipeline programs include two preclinical candidates, a PEG-colony stimulating factor protein engineered to selectively modulate resolution processes of inflammation and NKTR-0165, a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

Contact:

For Investors:

Vivian Wu of Nektar Therapeutics628-895-0661

For Media:

David Rosen of Argot Partners(212) 600-1902david.rosen@argotpartners.com

https://c212.net/c/img/favicon.png?sn=SF68010&sd=2024-03-22

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-management-to-present-at-the-hc-wainwright-2nd-annual-autoimmune--inflammatory-disease-virtual-conference-302097317.html

SOURCE Nektar Therapeutics

https://rt.newswire.ca/rt.gif?NewsItemId=SF68010&Transmission_Id=202403221400PR_NEWS_USPR_____SF68010&DateId=20240322

COMTEX_449665997/1005/2024-03-22T14:00:29